
Abemaciclib was granted a priority review to a new drug application (NDA) to treat patients with advanced hormone receptor (HR)­­–positive, HER2-negative breast cancer, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.





















